Biotech Firm Celularity Faces Nasdaq Delisting Threat Amid Financial Restructuring

Celularity Inc. finds itself navigating a critical period as it confronts potential delisting from the Nasdaq exchange. The biotechnology company has repeatedly failed to submit its quarterly financial reports on schedule, placing it in violation of the exchange’s listing requirements. This regulatory challenge follows an official notice of non-compliance issued to the company on August 21.

The situation has escalated after Celularity allowed an extension previously granted by Nasdaq to expire unused. The exchange had provided until August 31 for the company to comply, but this deadline passed without resolution. Celularity now faces a September 5 deadline to present an updated compliance plan to regulators. The absolute final date for submitting all outstanding financial documentation is November 17. Failure to meet these requirements could result in the removal of Celularity’s stock from the exchange—a development that would severely impact the company’s liquidity and investor accessibility.

Strategic Debt Elimination Through Intellectual Property Transaction

Amid these regulatory pressures, Celularity executed a significant financial maneuver in mid-August. On August 18, the company eliminated all outstanding senior secured debt obligations totaling $32.0 million, plus accrued interest of $9.6 million, for a combined settlement of $41.6 million.

This financial restructuring was achieved through an asset purchase agreement with Celeniv Pte. Ltd. that involved the sale of intellectual property assets. In exchange for the IP transfer, Celularity secured exclusive licensing rights for an initial five-year period and obtained an option to repurchase the assets in the future. The transaction effectively removed the general collateral agreement with creditors and fundamentally altered the company’s debt structure.

Should investors sell immediately? Or is it worth buying Celularity?

Key Upcoming Deadlines:
* September 5, 2025: Updated compliance plan due to Nasdaq
* November 17, 2025: Final deadline for all delinquent filings
* August 22, 2025: Nasdaq issued non-compliance notice for missing Q1/Q2 reports
* August 31, 2025: Original Nasdaq extension period lapsed unused
* August 18, 2025: Debt restructuring via IP sale completed

Additional Financing and Regulatory Developments

Concurrent with its debt resolution efforts, Celularity has undertaken additional financial arrangements. On August 1, the company issued a promissory note worth $6.8 million, scheduled to mature in March 2026 and secured against corporate assets. Separately, Celularity acquired preferred stock in Defeye, Inc. valued at $2.9 million.

A potential regulatory development may offer new opportunities for the stem cell technology company. A recently enacted Florida state law, effective since July 2025, now permits physicians to administer investigational stem cell therapies. Celularity has responded to this regulatory change by announcing a partnership with Fountain Life to supply therapeutic products for these emerging treatment applications.